Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)

NCT03679767 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT03679767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03679767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Completed
Start date
January 9, 2019
Completion date
June 28, 2022
Enrollment
121 (actual)
Sites
52

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced renal cell carcinoma, locally advanced urothelial cancer, metastatic clear-cell renal cell carcinoma, metastatic melanoma, metastatic non-small cell lung cancer, metastatic urothelial cancer, unresectable melanoma